The effect of amiodarone on the ventricular fibrillation threshold

Pharmacotherapy

Volumn 19, Issue 7, 1999, Pages 832-837

  Chen, Bonnie P ^a   White, C Michael ^a,b   Fan, Chengde ^a   Kluger, Jeffrey ^a,c   Chow, Moses S S ^d  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART ARREST; HEART VENTRICLE FIBRILLATION; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; RESUSCITATION; SURVIVAL; SWINE;

AMIODARONE; ANIMALS; BLOOD CIRCULATION; BLOOD GAS ANALYSIS; CARDIOPULMONARY RESUSCITATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMIC PROCESSES; HYDROGEN-ION CONCENTRATION; REFERENCE VALUES; SWINE; VASODILATOR AGENTS; VENTRICULAR FIBRILLATION; VENTRICULAR FUNCTION;

EID: 0032872685     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.10.832.31564     Document Type: Article

References (19)

1. Chow MSS. Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Ann Pharmacother 1996;30:637-43.
2. Lu HR, Remeysen P, De Clerk F. Antifibrillatory action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs. J Cardiovasc Pharmacol 1995;26:132-6.
3. Winkle RA, Mead RH, Ruder MA, et al. Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol 1989;13:1353.
4. Akhtar M, Jazayeri M, Sra J, et al. Implantable cardioverter defibrillator for prevention of sudden cardiac death in patients with ventricular tachycardia and ventricular fibrillation. PACE 1993;16:511.
5. Wever EFD, Hauer RNW, Crijns HJGM, et al. Dutch prospective randomized trial of implantable defibrillator as first-choice therapy in post-infarct sudden death survivors versus conventional strategy[abstr]. Eur J Cardiol 1994;15:344.
6. Chow MSS, Kluger J, DePersio DM, Lawrence R, Fieldman A. Antifibrillatory effects of lidocaine and bretylium immediately post-cardiopulmonary resuscitation. Am Heart J 1985;110:938-43.
7. Hanyok JJ, Chow MSS, Kluger J, et al. Antifibrillatory effect of high dose bretylium and lidocaine-bretylium combination during cardiopulmonary resuscitation. Crit Care Med 1988;16:691-4.
8. Cummins RO, ed. Textbook of advanced cardiac life support. Dallas, TX: American Heart Association, 1994.
9. University of Washington. Drug shows promise in keeping cardiac arrest patients alive until they reach the hospital. Press release, Seattle, WA, November 12, 1997.
10. Medical Education Network. Antiarrhythmia therapy significantly increases survival to hospital in patients with shock-refractory cardiac arrest. Presented at the 70th scientific session of the American Heart Association, Orlando, FL, November 9-12, 1997.
11. Arredondo MT, Guillen SG, Quinteiro RA. Effect of amiodarone on ventricular fibrillation and defibrillation thresholds in the canine heart under normal and ischemic conditions. Eur J Pharmacol 1986;125:23-8.
12. Anderson JL, Rodier HE, Green LS. Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol 1983;51:1196-1202.
13. Tisdale JE, Sun H, Zhao H, et al. Antifibrillatory effect of esmolol alone and in combination with lidocaine. J Cardiovasc Pharmacol 1996;27:376-82.
14. Lu HR, Remeysen P, De Clerck F. Antifibrillatory action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs. J Cardiovasc Pharmacol 1995;26:132-6.
15. Bui-Xuan B, Aupetit JF, Freysz M, Faucon G, Timour Q. Prevention by calcium antagonists of profibrillatory effects of class I antiarrhythmic drugs in acute myocardial ischemia: study in pig heart in situ. Pharmacotherapy 1997;17:737-45.
16. Liu P, Fei L, Wu W, Li J, Wang J, Zhang X. Effects of hypothyroidism on the vulnerability to ventricular fibrillation in dogs: a comparative study with amiodarone. Cardiovasc Drugs Ther 1996;103:369-78.
17. Zhou L, Chen BP, Kluger J, Fan C, Chow MSS. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol 1998;31:1672-8.
18. Honloser SH, Meinertz T, Dammbacher I, et al. Electrocardiographs and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-controlled study. Am Heart J 1991;121:89-95.
19. Morady F, DiCarlo LA, Krol RB, Baerman JM, DeBuitleir M. Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol 1986;7:148-57.